Cardiac arrest (CA) produces global
ischemia/reperfusion injury resulting in substantial multiorgan damage. There are limited efficacious
therapies to save lives despite CA being such a lethal disease process. The small population of surviving patients suffer extensive brain damage that results in substantial morbidity.
Mitochondrial dysfunction in most organs after CA has been implicated as a major source of injury.
Metformin, a first-line treatment for diabetes, has shown promising results in the treatment for other diseases and is known to interact with the mitochondria. For the treatment of CA, prior studies have utilized
metformin in a preconditioning manner such that animals are given
metformin well before undergoing CA. As the timing of CA is quite difficult to predict, the present study, in a clinically relevant manner, sought to evaluate the therapeutic benefits of
metformin administration immediately after
resuscitation using a 10 min asphxyial-CA rat model. This is the first study to show that
metformin treatment post-CA (a) improves 72 h survival and neurologic function, (b) protects mitochondrial function with a reduction in apoptotic
brain injury without activating AMPK, and (c) potentiates earlier normalization of brain electrophysiologic activity. Overall, as an effective and safe
drug,
metformin has the potential to be an easily translatable intervention for improving survival and preventing brain damage after CA.